Yes, Entyvio (vedolizumab) is a biologic medication. It belongs to a class called humanized monoclonal antibodies, which are proteins engineered in living cells rather than synthesized through traditional chemistry. The FDA has approved Entyvio for treating moderately to severely active ulcerative colitis and Crohn’s disease in adults.
What Makes Entyvio a Biologic
Biologics are drugs made from living organisms or their components, as opposed to conventional drugs built from chemical compounds. Entyvio is a large, complex protein grown in cell cultures and designed to interact with a very specific target in the body. This is what separates it from standard pills like corticosteroids or immunosuppressants, which are small molecules made through chemical synthesis.
More specifically, Entyvio is classified as an integrin receptor antagonist. It works by binding to a protein on the surface of certain immune cells that are headed toward the gut lining. By blocking that protein, Entyvio prevents those immune cells from reaching the intestinal wall and causing the inflammation that drives ulcerative colitis and Crohn’s disease.
How Entyvio Differs From Other Biologics
Many people with inflammatory bowel disease are familiar with TNF blockers, another category of biologics that includes widely prescribed options. TNF blockers work systemically, meaning they suppress inflammation throughout the entire body by neutralizing a key inflammatory signaling molecule. Entyvio takes a fundamentally different approach: it is gut-selective. Rather than dampening the immune system broadly, it specifically intercepts immune cells that are traveling to the gastrointestinal tract.
This selectivity matters for two reasons. First, it means Entyvio’s anti-inflammatory effects are concentrated where the disease actually lives. Second, because it doesn’t suppress the immune system body-wide, it carries a different safety profile than systemic biologics. That gut-selective mechanism is a large part of why doctors sometimes choose Entyvio over other biologics, particularly for patients concerned about systemic immune suppression.
Who Typically Gets Prescribed Entyvio
Entyvio is generally prescribed to adults whose disease hasn’t responded well enough to other treatments. In the clinical trials that led to its approval, patients enrolled in the U.S. had already tried immunosuppressant medications, TNF blockers, or both without adequate improvement, or they had lost response to those treatments over time, or they couldn’t tolerate them. Outside the U.S., some patients qualified if they were unable to taper off corticosteroids without their symptoms returning.
How It’s Given
Entyvio was originally developed as an intravenous (IV) infusion. The standard IV dose is 300 mg, given at a clinic or infusion center. During the initial phase, infusions are given at weeks 0, 2, and 6 to build up levels in the body. After that, maintenance infusions are typically scheduled every 8 weeks.
A subcutaneous (under-the-skin) injection form is also available for maintenance treatment. After completing at least two IV infusions, patients can switch to a 108 mg injection given every 2 weeks at home. Some physicians adjust this to weekly injections based on symptoms and lab markers. The at-home injection option has made ongoing treatment considerably more convenient for many patients.
How Long It Takes to Work
Entyvio tends to work more slowly than some other biologics, and this is important to know going in. In ulcerative colitis, clinical response can appear as early as 6 weeks after the first two induction doses. At that point in clinical trials, 47% of patients on Entyvio showed clinical response compared to 26% on placebo, and mucosal healing rates were 41% versus 25%.
For Crohn’s disease, the timeline is longer. Clinical remission typically takes at least 10 to 14 weeks, and real-world data suggest the median time to clinical response is closer to 19 weeks. Improvement often continues well beyond the initial months. In maintenance studies, remission rates and symptom scores kept improving all the way out to week 52, suggesting that the full benefit of Entyvio can take several months to materialize. Doctors generally consider 12 months a reasonable point to evaluate whether the drug is working before calling it a treatment failure.
Side Effects and Safety
The most commonly reported side effects are gastrointestinal symptoms and infections. Specifically, the side effects that occurred most frequently include nasopharyngitis (common cold symptoms), headache, joint pain, upper respiratory tract infections, nausea, abdominal pain, fever, vomiting, and anemia.
Infusion-related reactions occur in 5% or fewer of patients per study, making them relatively uncommon. Serious infections, including certain bacterial infections and sepsis, were reported in less than 1% of patients. Fewer than 1% of patients in clinical studies were diagnosed with a malignancy, though establishing a direct link to the drug is difficult in populations already at elevated risk.
One safety concern that comes up with a related class of drugs is progressive multifocal leukoencephalopathy (PML), a rare and dangerous brain infection. No cases of PML were observed in Entyvio’s clinical trial program, which is reassuring and likely related to its gut-selective mechanism rather than broad immune suppression. A small number of patients experienced liver-related events, though all cases resolved or nearly resolved with appropriate management.
Biosimilar Availability
As of early 2026, no biosimilar version of Entyvio has been approved by the FDA. While biosimilars exist for many other biologics used in inflammatory bowel disease, vedolizumab is not yet among them. This means Entyvio remains available only as the branded product, which can affect cost and insurance coverage considerations.